1. Home
2. Symposiums (SBIMC)
3. Symposiums
4. 43ième symposium

43ième symposium

A MIRROR BETWEEN NORTH AND SOUTH

• Key note lectures.

  • Spanish influenza, a long shadow. [Marc VAN RANST, UZ Leuven, Louvain)]
  • Management of Ebola disease. [Aura TIMEN (Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven, Pays-Bas)]
  • Point of care testing. [Jan JACOBS (ITG, Anvers)]

• Multidrug resistant tuberculosis.

  • The scope of the problem. [Bouke DE JONG (ITG, Anvers)]
  • Belgian experience. [Steven CALLENS (UZ Gent, Gand) et Marie-Christine Payen (CHU Saint-Pierre, Bruxelles)]
  • Dutch experience. [Tjip VAN DER WERF (UMC Groningen, Groningen, Pays-Bas)]

• Antibiotic stewardship.

  • The Dutch view: the A-teams. [Jan PRINS (AMC Amsterdam, Amsterdam, Pays-Bas)]
  • The Belgian approach: antimicobial management teams. [Willy PEETERMANS (UZ Leuven, Louvain)]
  • What to do in resource limited settings? [Erika VLIEGHE (ITG, Anvers)]

• Microbiology.

  • Evaluation of BinaxNOW Staphylococcus aureus and PBP2a culture colony test for rapid identification and resistance detection of Staphylococcus aureus on positive blood cultures. [Lydwine DEFOURNY0( Cliniques Universitaires Saint-Luc, Bruxelles)]
  • Is there evidence for a reservoir of carbapenemase producing Enterobacteriaceae in nurisng homes and rehabilitation centers? [Veroniek SAEGEMAN (UZ Leuven, Louvain)]
  • Improved diagnostics of vancomycin resistant enterococci by PCR on direct patient samples. [Sylvia BRUISTEN (GGD Amsterdam, Amsterdam, Pays-Bas)]
  • Ciprofloxacin and azithromycin resistance of Campylobacter spp. isolated from international travellers 2008-2014. [Niki VAN WATERSCHOOT Universiteit Maastricht, Maastricht, Pays-Bas)]

• Infectiology.

  • Current vancomycin dosing recommendations for pediatric patients: a pharmacokinetic evaluation. [Pieter-Jan CORTOOS (UZ Brussel, Bruxelles )]
  • The role of ZmpC in the clinical manifestation of invasive pneumococcal disease. [Amelieke CREMERS (UMC Radboud, Nijmegen, Pays-Bas)]
  • Cumulative incidence cannot be derived reliably frompoint prevalence surveillance data in Dutch hospitals. [Anouk MEIJS (Rijksinstituut voor Volks-gezondheid en Milieu, Bilthoven, Pays-Bas)]
  • Is the incidence of CLABSI influenced by compliance to an intervention bundle? [Emma SMID (Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven, Pays-Bas)]

• Writing and implementation of standard treatment guidelines.

  • Introduction. [William MALCOLM (NHS National Services Scotland, Glasgow, Royaume Uni)]
  • Writing and implementation of standard treatment guidelines. [Dirk VOGELAERS (UZ Gent, Gent) et Maarten VAN STEENKISTE (UGent, Gand)]
  • Guidelines. [Marc BONTEN (UMC Utrecht, Utrecht, Pays-Bas)]

• Can we treat carbapenemase and ESBL producers based on MIC? A pro-con debate.

  • Introduction. [James COHEN STUART (Noordwest Ziekenhuisgroep, Alkmaar, Pays-Bas)]
  • Pro. [Rafael CANTON (Hospital Universitario Ramon Y Cajal, Madrid, Espagne)]
  • Con. [David LIVERMORE (University of East Anglia, Norwich, Royaume Uni)]

• Keynote lecture.

  • The role of ECDC in the fight against antimicrobial resistance. [Marc SPRENGER (ECDC, Solna, Suède)]